H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) shares were down 49.5% on Thursday . The stock traded as low as $2.02 and last traded at $2.02. Approximately 400 shares changed hands during trading, an increase of 288% from the average daily volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5 %
The stock has a fifty day moving average of $2.02 and a 200-day moving average of $2.02.
H-CYTE Company Profile
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Further Reading
- Five stocks we like better than H-CYTE
- What is the Shanghai Stock Exchange Composite Index?
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- Expert Stock Trading Psychology Tips
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What is diluted earnings per share (Diluted EPS)?
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
